You just read:

Thought leaders are Optimistic that Emerging Therapies for Previously Treated EGFR-Mutation-Positive NSCLC will Offer Competitive Advantages over Currently Available Treatments

News provided by

Decision Resources Group

Apr 29, 2014, 10:00 ET